PE-22-28
Also known as: spadin analog, TREK-1 blocker
By GLPeptideSciences Editorial Team · How we evaluate evidence · Reviewed by Dr. George S. Watson, MD, Cardiothoracic Surgeon · Updated 2026-06-02
A peptide derived from spadin, studied in animal models as a potential rapid-acting antidepressant through TREK-1 channel blockade.
What it is & how it works
What it is
PE-22-28 is a peptide derived from spadin, studied as a candidate fast-acting antidepressant mechanism in laboratory models.
How it is thought to work
It’s associated with blocking the TREK-1 potassium channel, a target linked to mood regulation and neuroplasticity.
The evidence and the caveat
All of the antidepressant-like findings are preclinical. There is no human trial data, so it remains a research-stage concept rather than a validated intervention.
What it's discussed & studied for
- Mood and antidepressant research (preclinical)
- Neuroplasticity discussion
Discussion of a use is not a claim that it works or is approved.
Research status
Preclinical. Antidepressant-like effects in rodent models; no human trial data. Not approved.
Evidence quality
Mechanistically interesting animal work, no human validation. Read as preclinical.
Dosing discussion
No human protocol exists; anything circulating is extrapolated from animal studies.
Educational summary of what is discussed in the literature and community — not a dosing recommendation or medical advice.
Safety & harm reduction
Human safety is uncharacterized; the absence of human data is the key limitation.
Sourcing literacy
No approved product; research-market material is unverified.
Selected literature
FAQ
What is TREK-1 and why does it matter here?
TREK-1 is a potassium channel linked to mood regulation; blocking it is the proposed antidepressant mechanism for spadin-derived peptides like PE-22-28 — so far only in animal models.